


FLUID OVERLOAD:


THE PREVENTABLE CAUSE OF ICU-RELATED ACUTE KIDNEY INJURY



1. The Hidden Driver of AKI

Acute Kidney Injury (AKI) affects up to 40–60% of ICU patients and is associated with increased mortality, prolonged hospitalization, and progression to chronic kidney disease. Traditionally, AKI in critical illness has been attributed to hypotension, ischemia-reperfusion injury, and sepsis-related inflammation.^{1,2}

However, growing evidence suggests that fluid overload is not merely a consequence of critical illness—it may directly contribute to renal dysfunction and poorer outcomes.^{1,3}



2. Rethinking AKI: The Role of Congestion

Renal Venous Congestion and Interstitial Edema.⁴

The kidneys are particularly vulnerable to congestion because of their low-pressure vascular bed and relatively non-compliant capsule. Elevated renal venous pressure can reduce glomerular filtration even when arterial perfusion appears adequate.⁴

Payen et al. demonstrated that a positive cumulative fluid balance was independently associated with increased mortality and organ dysfunction, including AKI.^{5,6}

CLINICAL CLUES

Congestion-driven AKI may present with:

- Oliguria unresponsive to fluid boluses
- Rising serum creatinine with generalized edema
- Elevated central venous pressure or venous Doppler abnormalities
- Worsening oxygenation accompanying fluid accumulation^{4,5}



3. When More Fluid Becomes Harmful


Intravenous fluids remain essential during early shock resuscitation. However, beyond initial stabilization, continued liberal fluid administration may become increasingly harmful.^{1,7}

KDIGO recommends a phase-based approach¹² to fluid management:

- Resuscitation
- Stabilization
- De-resuscitation¹²

Practical strategies include:

- Early vasopressor initiation
- Dynamic assessment of fluid responsiveness
- Discontinuation of unnecessary maintenance fluids
- Early transition to neutral or negative fluid balance^{7,12}



4. Fluid Overload and Renal Replacement Therapy

Traditionally, the decision to initiate Renal Replacement Therapy (RRT) focused on metabolic and electrolyte abnormalities. Increasing evidence now supports fluid overload as an important indication for intervention.^{8,9}

Bouchard et al. reported significantly higher mortality and lower rates of renal recovery among AKI patients who initiated RRT with greater than 10% fluid accumulation relative to body weight.⁹

Recent KDIGO recommendations advocate individualized timing of RRT based on:

- Degree of fluid overload
- Respiratory status
- Feasibility of conservative fluid removal^{7,8}




5. Can Albumin Support Fluid Stewardship?

In sepsis and systemic inflammation, capillary leak reduces the effectiveness of crystalloids. Albumin may help restore circulating volume with less overall fluid exposure, potentially limiting tissue edema and fluid accumulation.¹⁰

Evidence from the SAFE and ALBIOS trials supports its safety and suggests benefits such as improved hemodynamics, reduced vasopressor requirements, and lower cumulative fluid balance in selected patients.^{10,11}

Current KDIGO guidance recommends a selective, individualized approach, particularly in hypoalbuminemic patients with fluid overload.⁷



6. Looking Beyond Blood Pressure


Managing AKI is no longer solely about restoring perfusion. Increasing evidence suggests that congestion and fluid accumulation are important drivers of renal injury—even when conventional hemodynamic targets are achieved.^{3,5}

Recognizing fluid overload early and adopting a stewardship approach to fluid therapy may offer an opportunity to improve both renal and patient-centered outcomes.^{7,12}

Key Takeaways

- Fluid overload independently worsens AKI outcomes
- ✓ Congestion-driven AKI can occur despite preserved blood pressure
- ✓ Fluid accumulation should influence RRT timing decisions
- ✓ Albumin may have a selective role in fluid stewardship and de-resuscitation

Clinical Pearl



Treat fluids like a drug. The right fluid, in the right patient, at the right time can be lifesaving. Beyond that point, avoiding fluid overload may be equally important.

By scanning the code, you will be directed to the API of Flexbumin, an external website which is owned and managed by Takeda



API of Flexbumin



*The cases presented are hypothetical and intended for illustrative purposes only. The management strategies discussed are evidence-based and aligned with established clinical guidelines and scientific literature.

Disclaimer:

This information is solely intended for the use of Registered Healthcare Practitioner / Registered Medical Practitioner only. This information should not be used, shared, or distributed to any other person / party and should be strictly used by the intended parties for the intended purposes only. Registered Healthcare Practitioner / Registered Medical Practitioner shall apply their independent medical judgment for assessing any patient. Takeda makes no representation or warranty concerning the information / content provided, and assumes no responsibility for the accuracy of the information or content or for any opinion furnished or any outcome based on the application of such information. This material contains copyright protected information, content; the use of which is limited by law and this material cannot be reproduced, replicated, used or modified by any person for their own use or further distribution. For more information, please refer to full Prescribing Information.

TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. Flexbumin[®] is a trademark or registered trademark of Baxalta Incorporated. Copyright (C) 2026 Takeda Pharmaceutical Company. All Rights Reserved.*

References:

1. Malbrain MLNG, Marik PE, Winters I, et al. Fluid overload, de-resuscitation, and outcomes in critically ill patients. *Annals of Intensive Care*. 2014;4:16.
2. Divatia JV, Amin PR, Ramakrishnan N, et al. Intensive care in India: The INDI-CAPS study. *Indian Journal of Critical Care Medicine*. 2016;20(4):216–225.
3. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2021. *Intensive Care Medicine*. 2021;47:1181–1247.
4. Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM. Hypoalbuminemia in acute illness: Is there a rationale for intervention? *Annals of Surgery*. 2003;237(3):319–334.
5. Caironi P, Tognoni G, Masson S, et al. Albumin replacement in patients with severe sepsis or septic shock (ALBIOS trial). *New England Journal of Medicine*. 2014;370:1412–1421.
6. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit (SAFE study). *New England Journal of Medicine*. 2004;350:2247–2256.
7. Caironi P, Tognoni G, Masson S, et al. Albumin replacement therapy in severe sepsis and septic shock. *New England Journal of Medicine*. 2014;370:1412–1421.
8. Acheampong A, Vincent JL. A positive fluid balance is an independent prognostic factor in critically ill patients. *Critical Care*. 2015;19:251.
9. Kumar HG, Kanakaraju K, Manikandan VAC, et al. The relationship between serum albumin levels and sepsis in patients admitted to a tertiary care center in India. *Cureus*. 2024;16(4):e59424.
10. Mornet X, Marik PE, Teboul JL. Prediction of fluid responsiveness: An update. *Annals of Intensive Care*. 2016;6:111.
11. Malbrain MLNG, Van Regenmortel N, Saugel B, et al. Principles of fluid management and stewardship in septic shock. *Intensive Care Medicine*. 2018;44:117–130.
12. Hoste EA, Maitland K, Brudney CS, et al. Four phases of intravenous fluid therapy: A conceptual model. *British Journal of Anaesthesia*. 2014;113(5):740–747.